For inherited retinal diseases, the first clinical trial based on AONs to redirect a splicing defect in CEP290 has recently shown promising results,21 whereas a second one, for USH2A, is currently ongoing (ClinicalTrials.gov: NCT03780257). Here, CEP290 is linked to Abnormal retinal morphology.